Suven Pharmaceuticals Limited
Suven Pharmaceuticals Limited (SPL), a company incorporated in November 2018, has become Wholly Owned Subsidiary of Suven Life Sciences Limited, effective February 2019.
Suven Life Sciences Limited, the demerged entity, to continue innovative research focused on Central Nervous System (CNS) disorders to meet huge unmet global medical needs. Suven Pharmaceuticals Limited, the resultant entity, to continue the Contract Research and Manufacturing Services Undertaking (CRAMS) business operations.
SPL recognizes that business enterprises are economic organs of society and part of society and draw on societal resources for their growth. SPL’s CSR policy focuses on building economic, social, and environmental capital while ensuring greater stake-holder value. It wishes to conduct business in a socially responsible, responsive, and ethical manner while ensuring economic and social sustainability and promoting healthcare initiatives, environment, and providing for inclusive growth.
For the quarter ended 31-03-2021, the company has reported a Consolidated Total Income of Rs 262.46 Crore, fell by 6.19% from last quarter Total Income of Rs 279.78 Crore and up 38.06% from last year same quarter Total Income of Rs 190.10 Crore. Company has reported net profit of Rs 83.12 Crore in latest quarter. The Board of Directors decided to recommend a Final Dividend @ Rs.1 per equity share of Rs.1 each for the financial year 2020-21.
The results of FY21 were competent.
